Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]

Inclusion Criteria: * Histologically/cytologically proven prostate adenocarcinoma * Progression or non response with previous chemotherapy regimen (excluding Taxotere®) * Received previous mitoxantrone/prednisone or one other chemotherapy regimen including emcyt +/- vinblastine * Castration levels of testosterone (\<50 ng/dL ) * ECOG performance status 0-2 * Laboratory requirements : 1. Hematology: * Neutrophils ≥ 1.5 x 10\^9/L * Hemoglobin \> 10 g/dL (prior transfusion permitted). * Platelets ≥ 100 x 10\^9/L 2. Hepatic function: * Total bilirubin \< the upper-normal limit of the institution. * ALAT (SGPT) and ASAT (SGOT) ≤ 1.5 times the upper-normal limit of the institution. 3. Renal function: * Creatinine ≤1.5 times the upper normal limit (i.e., NCI grade ≤1) * No severe or uncontrolled disease Exclusion Criteria * Chemotherapy within the last 4 weeks * Anti-androgen therapy within the last 4 weeks. * Prior malignancy except the following: adequately treated non-melanomatous skin cancer and superficial bladder cancer from which the patient has been disease-free for \>2 years. * Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening. * Treatment with any other anti-cancer therapy (except LHRH agonists) including any prescribed compounds and/or OTC products for the treatment of prostate cancer must be stopped prior to study entry. * Other serious illness, psychiatric or medical condition that would not permit the patient to be managed according to the protocol including active uncontrolled infection and significant cardiac dysfunction.